ArticleERJ open research2026
Improvements in small airway dysfunction and respiratory symptoms following tezepelumab for severe asthma.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Impact of Biologics on Oscillometry Defined Small Airway Dysfunction in Uncontrolled Asthma.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Review
- Navigating the small airways with tezepelumab.ERJ open research · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small airway dysfunction (SAD) is a key feature of severe asthma, contributing to poor symptom control and exacerbations. Tezepelumab has demonstrated efficacy in reducing exacerbations and improving lung function, but its specific effects on SAD remain underexplored. We aimed to assess changes in SAD among patients initiating tezepelumab. Methods: A prospective observational study was carried out among patients with severe asthma treated with tezepelumab in a tertiary centre. SAD was assessed at baseline and 6 months using impulse oscillometry (IOS) and spirometry. We focused on frequency dependence of resistance ( Results: 34 patients were included (median age 60 years, 74% females, 21% biologic-experienced) with a median follow-up of 183 days. There were significant improvements from baseline to follow-up in forced expiratory volume in 1 s (FEV Conclusion: Tezepelumab significantly improved small airway function, which was associated with better asthma control. Our findings highlight SAD as a treatable trait in patients with severe asthma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.